Arca
Skip to content
Tools
Tools

Interstitial cystitis

Drug research and approvals for interstitial cystitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 23 studies of interstitial cystitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and FDA has 1 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 23
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest start dates first, of 23 recruiting on ClinicalTrials.gov ↗

Drug pipeline

1 approved, 11 in phase 3, 14 in phase 2, 7 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Pentosan polysulfate sodium

Amitriptyline
Phase 3 Serotonin transporter inhibitor
Rosiptor
Phase 3 Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 activator
Certolizumab pegol
Phase 3 TNF-alpha inhibitor
Mycophenolate mofetil
Phase 3 Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Omalizumab
Phase 3 Ig epsilon chain C region inhibitor
Estrogens, conjugated
Phase 3 Estrogen receptor agonist
Adalimumab
Phase 3 TNF-alpha inhibitor
Triamcinolone acetonide
Phase 3 Glucocorticoid receptor agonist
Mirabegron
Phase 3 Beta-3 adrenergic receptor agonist
Methenamine
Phase 3 DNA inhibitor
Gabapentin
Phase 3 Voltage-gated calcium channel modulator
Onabotulinumtoxina
Phase 2 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
Lidocaine
Phase 2 Sodium channel alpha subunit blocker
Heparin
Phase 2 Antithrombin-III activator
Dimethyl sulfoxide
Phase 2 Unknown
Tanezumab
Phase 2 Beta-nerve growth factor inhibitor
Cyclosporine
Phase 2 Cyclophilin A modulator
Naltrexone
Phase 2 Opioid receptors; mu/kappa/delta antagonist
Gefapixant
Phase 2 P2X purinoceptor 3 antagonist
Fremanezumab
Phase 2 Calcitonin gene-related peptide antagonist
Interferon
Phase 2
Tipelukast
Phase 2
Ozone
Phase 2
PD-0299685
Phase 2
Cannabidiol
Phase 1 Cannabinoid CB1 receptor negative allosteric modulator
Sunobinop
Phase 1
Ferumoxytol
Early phase 1 Unknown

Showing the 30 furthest along of 32 in trials.

How its trials ended

214 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 48 whose ending is known, 13% met their primary endpoint, 10% missed it and 77% stopped early.

  • Completed, result not reported10850%
  • Ongoing3617%
  • Stopped: other or unclear2311%
  • Status unknown2210%
  • Met its primary endpoint63%
  • Missed its primary endpoint52%
  • Stopped: enrollment or feasibility42%
  • Stopped: sponsor or business decision42%
  • Stopped: lack of efficacy31%
  • Stopped: funding21%
  • Stopped: safety10%

Trials authorized in Canada

Newest first; search them all in Canada trials
Feb 25, 2022A multicenter, randomized, double-blind, placebo-controlled, parallel arm study to assess the safety and efficacy of a single treatment of botox®, followed by…BotoxAbbVieClosed
Jul 3, 2020Efficacy and safety of fremanezumab for treatment of female patients with ic-bpsAjovy (fremanezumab)Teva Pharmaceutical IndustriesPending
Jul 29, 2016The leadership 301 trial: a 12-week, randomized, multi-center, double-blind, placebo-controlled, 3-arm, parallel-group, phase 3 trial to evaluate the efficacy…AQX-1125Aquinox Pharmaceuticals IncClosed
Jun 18, 2015A multicenter, randomized, double-blind, placebo-controlled study, evaluating safety and efficacy of liris® 400 mg in females with interstitial…LirisAbbVieClosed
May 14, 2015A multicenter, randomized, double-blind, placebo-controlled study, evaluating safety and efficacy of liris® 400 mg in females with interstitial cystitis with…LirisAbbVieClosed
May 30, 2013The leadership study: a phase II study to evaluate the efficacy and safety of AQX-1125 in subjects with interstitial cystitis/bladder pain syndrome mediated by…AQX-1125Aquinox Pharmaceuticals IncOngoing
Apr 10, 2013A phase 2a multicenter, randomized, double-blinded, placebo-controlled study evaluating safety, tolerability and efficacy of liris® 400 mg in women with…LirisTaris Biomedical IncClosed

FDA orphan designations

Approved first, then open designations, newest first
Sep 26, 1996ElmironRelief of bladder pain or discomfort associated with interstitial cystitis.Alza CorporationApproved
Jun 13, 1991NifedipineTreatment of interstitial cystitis.Fleischmann, Jonathan M.D.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.